Ahead of a hearing on pharmacy benefit managers before the House Committee on Oversight and Accountability on Tuesday, PhRMA released Nephron Research that contends PBMs are driving up profits and drug prices through
PBMs are driving up drug prices through fees, PhRMA report claims
